These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 26794595

  • 1. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
    Vanmierlo T, Creemers P, Akkerman S, van Duinen M, Sambeth A, De Vry J, Uz T, Blokland A, Prickaerts J.
    Behav Brain Res; 2016 Apr 15; 303():26-33. PubMed ID: 26794595
    [Abstract] [Full Text] [Related]

  • 2. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
    Jabaris SG, Sumathy H, Kumar RS, Narayanan S, Thanikachalam S, Babu CS.
    Eur J Pharmacol; 2015 Jan 05; 746():138-47. PubMed ID: 25446433
    [Abstract] [Full Text] [Related]

  • 3. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
    Blokland A, Van Duinen MA, Sambeth A, Heckman PRA, Tsai M, Lahu G, Uz T, Prickaerts J.
    Neurobiol Aging; 2019 May 05; 77():37-43. PubMed ID: 30776650
    [Abstract] [Full Text] [Related]

  • 4. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[11C]Rolipram.
    Takano A, Uz T, Garcia-Segovia J, Tsai M, Lahu G, Amini N, Nakao R, Jia Z, Halldin C.
    Mol Imaging Biol; 2018 Aug 05; 20(4):615-622. PubMed ID: 29441434
    [Abstract] [Full Text] [Related]

  • 5. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
    Wang H, Zhang FF, Xu Y, Fu HR, Wang XD, Wang L, Chen W, Xu XY, Gao YF, Zhang JG, Zhang HT.
    Int J Neuropsychopharmacol; 2020 Dec 10; 23(10):700-711. PubMed ID: 32645141
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R.
    Pulm Pharmacol Ther; 2006 Dec 10; 19(5):343-52. PubMed ID: 16257550
    [Abstract] [Full Text] [Related]

  • 7. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
    Feng H, Wang C, He W, Wu X, Li S, Zeng Z, Wei M, He B.
    Metab Brain Dis; 2019 Apr 10; 34(2):583-591. PubMed ID: 30610438
    [Abstract] [Full Text] [Related]

  • 8. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL.
    J Pharmacol Exp Ther; 2009 Sep 10; 330(3):922-31. PubMed ID: 19498103
    [Abstract] [Full Text] [Related]

  • 9. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
    McDonough W, Aragon IV, Rich J, Murphy JM, Abou Saleh L, Boyd A, Koloteva A, Richter W.
    FASEB J; 2020 Sep 10; 34(9):12533-12548. PubMed ID: 32738081
    [Abstract] [Full Text] [Related]

  • 10. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
    Böhmer GM, Gleiter CH, Mörike K, Nassr N, Walz A, Lahu G.
    J Clin Pharmacol; 2011 Apr 10; 51(4):594-602. PubMed ID: 20484614
    [Abstract] [Full Text] [Related]

  • 11. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H.
    Pulm Pharmacol Ther; 2010 Aug 10; 23(4):235-56. PubMed ID: 20381629
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.
    Barone FC, Barton ME, White RF, Legos JJ, Kikkawa H, Shimamura M, Kuratani K, Kinoshita M.
    Pharmacology; 2008 Aug 10; 81(1):11-7. PubMed ID: 17726343
    [Abstract] [Full Text] [Related]

  • 13. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G, Nassr N, Herzog R, Elmlinger M, Ruth P, Hinder M, Huennemeyer A.
    J Clin Pharmacol; 2011 Apr 10; 51(4):586-93. PubMed ID: 20466871
    [Abstract] [Full Text] [Related]

  • 14. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
    Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB.
    J Pharmacol Exp Ther; 2014 Jul 10; 350(1):153-63. PubMed ID: 24784567
    [Abstract] [Full Text] [Related]

  • 15. Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP/CREB signaling system.
    Jabaris SS, Sumathy H, Girish R, Narayanan S, Sugumar M, Saravana Babu C, Thanikachalam S, Thanikachalam M.
    Brain Res; 2015 Oct 05; 1622():279-91. PubMed ID: 26168894
    [Abstract] [Full Text] [Related]

  • 16. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
    Lahu G, Facius A.
    Int J Clin Pharmacol Ther; 2013 Nov 05; 51(11):832-6. PubMed ID: 24152603
    [Abstract] [Full Text] [Related]

  • 17. FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects.
    Guo H, Cheng Y, Wang C, Wu J, Zou Z, Niu B, Yu H, Wang H, Xu J.
    Neuropharmacology; 2017 Apr 05; 116():260-269. PubMed ID: 28065587
    [Abstract] [Full Text] [Related]

  • 18. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
    Moodley T, Wilson SM, Joshi T, Rider CF, Sharma P, Yan D, Newton R, Giembycz MA.
    Mol Pharmacol; 2013 Apr 05; 83(4):894-906. PubMed ID: 23389862
    [Abstract] [Full Text] [Related]

  • 19. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
    de Bruin NM, Prickaerts J, van Loevezijn A, Venhorst J, de Groote L, Houba P, Reneerkens O, Akkerman S, Kruse CG.
    Neurobiol Learn Mem; 2011 Sep 05; 96(2):392-402. PubMed ID: 21757018
    [Abstract] [Full Text] [Related]

  • 20. GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses.
    Bruno O, Fedele E, Prickaerts J, Parker LA, Canepa E, Brullo C, Cavallero A, Gardella E, Balbi A, Domenicotti C, Bollen E, Gijselaers HJ, Vanmierlo T, Erb K, Limebeer CL, Argellati F, Marinari UM, Pronzato MA, Ricciarelli R.
    Br J Pharmacol; 2011 Dec 05; 164(8):2054-63. PubMed ID: 21649644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.